



Testosterone Propionate Injection

Testosterone Propionate Injection BP 10 mg/mL
Testosterone Propionate Injection BP 25 mg/mL
Testosterone Propionate Injection BP 50 mg/mL 3 Yrs
Testosterone Propionate Injection BP 100mg/mL
Testosterone Propionate Injection BP 200mg/mL

COMPOSITION:

Each 2ml ampoule.:

Testosterone Propionate.....50mg

Each 2ml ampoule.:

Testosterone Propionate.....200mg/2ml

SUBSTANCE: Testosterone Propionate USP

CONTENT: Available in: 200mg/1ml/2ml amp./10ml Vial

Testosterone

Testosterone Propionate inj.

The most common dosage schedule for Testosterone Propionate (men) is to inject 50 to 100 mg, every 2nd or 3rd day. As with the more popular esters, the total weekly dosage would be in the range of 200-400 mg. As with all testosterone compounds, this drug is most appropriately suited for bulking phases of training. Here it is most often combined with other strong agents such as Dianabol, Anadrol 50 or Deca-Duralin, combinations that prove to be quite formidable. Propionate however is sometimes also used with non aromatizing anabolics/androgens during cutting or dieting phases of training, a time when its' fast action and androgenic nature are also appreciated. Popular stacks include a moderate dosage of propionate with an oral anabolic like Winstrol (15-35 mg daily), Primobolan (50-150 mg daily) or Oxandrolone (15-30 mg daily). Provided the body fat percentage is sufficiently low, the look of dense muscularity can be notably improved (barring any excess estrogen buildup from the testosterone). We can further add a non-aromatizing androgen like Trenbolone, which should have an even more extreme effect on subcutaneous body fat and muscle hardness. Of course with the added androgen content any related side effects will become much more pronounced.

INDICATIONS:

Testosterone propionate is a commonly manufactured, oil-based injectable testosterone compound. The added propionate ester will slow the rate in which the steroid is released from the injection site, but only for a few days. Testosterone propionate is therefore comparatively much faster acting than other testosterone esters such as cypionate or enanthate, and requires a much more frequent dosing schedule. While cypionate and enanthate are injected on a weekly basis, propionate is generally administered (at least) every third day. Figure one illustrates a typical release pattern after injection. As you can see, levels peak and begin declining quickly with this ester of testosterone.



To make Testosterone Propionate even more uncomfortable to use, the propionate ester can be very irritating to the site of injection. In fact, many sensitive individuals choose to stay away from Testosterone Propionate completely, their body reacting with a pronounced soreness and low-grade fever that may last for a few days. Even the mild soreness that is experienced by most users can be quite uncomfortable, especially when taking multiple injections each week. The standard esters like enanthate and cypionate, which are clearly easier to use, are therefore much more popular among athletes

Those who are not bothered by frequent injections will find that propionate is quite an effective steroid. It is of course of powerful mass drug, capable of producing rapid gains in size and strength. At the same time the buildup of estrogen and DHT (dihydrotestosterone) will be pronounced, so typical testosterone side effects are to be expected. Some do consider Testosterone Propionate to be the mildest testosterone ester, and the preferred form of this hormone for dieting/cutting phases of training. Some will go so far as to say that propionate will harden the physique, while giving the user less water and fat retention than one typically expects to see with a testosterone. Realistically however, this is nonsense. The ester is removed before testosterone is active in the body, and likewise the ester cannot alter the activity of the parent steroid in any way, only slow its release. We can say that propionate might be the favored testosterone among female bodybuilders (for those who insist on testosterone use!) as blood levels are easier to control with it compared to other esters. Should virilization symptoms develop, one would not wish to wait the weeks needed for testosterone concentrations to fall after a shot of enanthate for example.

During a typical Testosterone Propionate cycle one will see action that is consistent with a testosterone. Users sensitive to gynecomastia may therefore need to addition an antiestrogen. Those particularly troubled may find that a combination of Nolvadex and Proviron works especially well at preventing/halting this occurrence. Also unavoidable with a testosterone are androgenic side effects like oily skin, acne, increased aggression and body/facial hair growth. Those who may have a predisposition for male pattern baldness may also find that propionate will aggravate this condition. To help combat this we also have the option of adding Proscar, which will reduce the buildup of DHT in many androgen target tissues. This will help minimize related side effects (particularly hair loss) although it offers us no guarantees. And as with all testosterone products, propionate will also suppress endogenous testosterone production. The use of a testosterone stimulating drug like HCG and/or Clomid is therefore almost a requirement in order to avoid enduring a post-cycle crash.



The most common dosage schedule for Testosterone Propionate (men) is to inject 50 to 100 mg, every 2nd or 3rd day. As with the more popular esters, the total weekly dosage would be in the range of 200-400 mg. As with all testosterone compounds, this drug is most appropriately suited for bulking phases of training. Here it is most often combined with other strong agents such as Dianabol, Anadrol 50 or Deca-Durabolin, combinations that prove to be quite formidable. Propionate however is sometimes also used with non aromatizing anabolics/androgens during cutting or dieting phases of training, a time when its' fast action and androgenic nature are also appreciated. Popular stacks include a moderate dosage of propionate with an oral anabolic like Winstrol (15-35 mg daily), Primobolan (50-150 mg daily) or Oxandrolone (15-30 mg daily). Provided the body fat percentage is sufficiently low, the look of dense muscularity can be notably improved (barring any excess estrogen buildup from the testosterone). We can further add a non-aromatizing androgen like Trenbolone, which should have an even more extreme effect on subcutaneous body fat and muscle hardness. Of course with the added androgen content any related side effects will become much more pronounced.

Women who absolutely must use an injectable testosterone should only use this preparation. The Testosterone Propionate dosage schedule should also be more spread out for a female bodybuilder, with injections coming every 5 to 7 days. The dosage obviously would be lower as well, generally in the range of 25 mg to 50 mg per injection. Androgenic activity should be less pronounced with this schedule, giving blood levels time to sufficiently decrease before the drug is administered again. In order to further reduce any risks, the duration of this cycle should not exceed 8 weeks. Should a stronger anabolic effect be needed, a small amount of Duramin (Deca-Duralin if unavailable), Oxandrolone or Winstrol could be added. Of course the risk of noticing virilizing effects from these drugs may increase, even with the addition of a mild anabolic. Since many of the masculinizing side effects of steroid use can be irreversible, it is very important for the female athlete to monitor the dosage, duration and incidence of side effects very closely.

COMPOSITION:

Each Injection 100 mg. ampoule contains :

Testosterone propionate 25 mg. & Testosterone Ethan-ate 110 mg

Each Injection 250 mg. ampoule contains :

Testosterone Ethan-ate 250 mg.

MODE OF ACTION:

Testosterone Propionate : It is a highly anabolic as well as androgenic steroid. It is a common oil-based injectable testosterone. The added propionate extends the activity of the testosterone but it is still comparatively much faster acting than other testosterone esters such as cypionate and enanthate. Propionate is most commonly injected at least every third day to keep blood levels steady. This drug is quite effective for strength and muscle mass gains. Propionate is often very painful injection.

Testosterone enanthate : It is derivative of the primary endogenous androgen testosterone, for intra muscular administration. In their active form, androgens have a 17-beta hydroxy group. Esterification of the 17-beta-hydroxy group increases the duration of action of testosterone, hydrolysis to free testosterone occurs in vivo.





CLINICAL PHARMACOLOGY: Endogenous androgen are responsible for the normal growth and development of the male sex organs and for maintenance of secondary sex characteristics. These effects include growth and maturation of prostate, seminal vesicles, penis and scrotum, development of male hair distribution such as beard, pubic, chest and axillary hair, laryngeal enlargement, vocal chord thickening, alterations in body musculature and fat distribution.

PHARMACOKINETICS:

Testosterone esters less polar than free testosterone. Testosterone esters in oil injected intramuscularly are absorbed slowly from the lipid phase, thus testosterone enantate can be given at intervals of two to four weeks.

Testosterone in plasma is 98% bound to a specific testosterone estradiol binding globulin and about 2 % is free. The free testosterone concentrate will determine its half life.

About 90% of a dose of testosterone is excreted in the urine as glucuronic and sulfuric acid conjugates of testosterone and its metabolites, about 6 % of a dose is excreted in the feces, mostly in the unconjugated form.

INDICATIONS:

MALES:

Testosterone is indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone. Primary Hypogonadism (Congenital or acquired) : Testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome or orchidectomy. Hypogonadotropic Hypogonadism (Congenial or acquired): Idiopathic gonadotropin or leuteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma or radiation. Delayed Puberty : Testosterone may be used to stimulate puberty in carefully selected males with clearly delayed puberty.

FEMALES:

Metastatic mammary cancer : Testosterone may be used secondarily in women with advancing inoperable metastatic (skeletal) mammary cancer who are one to five years post menopausal.

DOSAGE AND ADMINISTRATION:

Total doses above 400 mg per month are not required because of the prolonged action of the preparation.

Male Hypogonadism: As replacement therapy i.e. For eunuchism, the dosage is 50 to 400 mg every 2 to 4 weeks.

In Males with Delayed Puberty: Dosage is within the range of 50 to 200 mg, every 2 to 4 weeks for a limited duration (4 to 6 months).

In Females: Palliation of Inoperable Mammary Cancer : A dosage of 200-400 mg every 2 to 4 weeks is recommended.

SIDE EFFECTS:

IN MALES:

Gynecomastia and excessive frequency and duration of penile erections, Hirsutism, Male pattern baldness, Acne, Retention of salts & water ,Nausea, Cholestatic jaundice, Suppression of clotting factor, Increased or decreased libido, Headache, Anxiety and depression.

IN FEMALES:

Amenorrhoea and other menstrual irregularities, inhibition of gonadotropic secretion and virilization, including deepening of the voice and clitoral enlargement.

CONTRAINDICATIONS:

Androgens are contraindicated in men with carcinomas of the breast or with known or suspected carcinomas of the prostate and in women who are or may become pregnant.





PRECAUTIONS:

Peliosis hepatis can be fatal complication, The androgen should be discontinued, if cholestatic hepatitis with jaundice appears.

Geriatric patients may be at the risk for the development of prostatic hypertrophy and prostatic carcinoma.

Caution is required in patients with pre existing cardiac, renal or hepatic disease, due to sodium and water retention properties of androgens.

DRUG INTERACTIONS:

When administered concurrently, the following drugs may interact with androgens :

Oral anticoagulants, Antidiabetic drugs and insulin, ACTH & corticosteroids, oxyphenbutazone.

STORAGE:

Testosterone Inj. should be stored at room temperature.

PRESENTATION:

1 ampoule of Testosterone DEPOT INJECTION 100 mg contains: Testosterone propionate 25 mg & Testosterone enanthate 110 mg

1 ampoule of Testosterone DEPOT INJECTION 250 mg contains: Testosterone enanthate 250 mg

For Information about Generic Medicines : genericmedicines@tajpharma.com

Note : This product information is intended only for residents of the India. Taj Pharmaceuticals Limited, medicines help to treat and prevent a range of conditions—from the most common to the most challenging—for people around the world. The Price of the drugs indicated above may not match the actual price at which they are sold. Prices can change depending on many factors, including local taxes. These are only approximate indicative prices of the drug. The products discussed herein may have different product labelling in different countries. The product information provided in this site is intended only for the residents of India.

Information for Health Care Professionals

*** Please consult local Prescribing Information for any product before use. This website is an international information resource for healthcare professionals with an interest in disease management. This website is not intended to replace the advice of a qualified healthcare professional. Above brand is a trademark of the Taj group of companies (Taj Pharmaceuticals Limited).





THIS PRESENTATION IS NOT AN ADVERTISEMENT OF SECURITIES IN ANY JURISDICTION.

NOT FOR RELEASE, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN.

This document includes statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the fact that they do not only relate to historical or current events. Forward-looking statements often use words such as "anticipate", "target", "expect", "estimate", "intend", "expected", "plan", "goal" believe, or other words of similar meaning. By their nature, forward-looking statements involve risk and uncertainty because they relate to future events and circumstances, a number of which are beyond Company's control. As a result, actual future results may differ materially from the plans, goals and expectations set out in these forward-looking statements. Any forward-looking statements made by or on behalf of the Company speak only as at the date of this announcement. Save as required by any applicable laws or regulations, the Company undertakes no obligation publicly to release the results of any revisions to any forward-looking statements in this document that may occur due to any change in its expectations or to reflect events or circumstances after the date of this document. The securities referred to herein have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States or to US persons unless the securities are registered under the Securities Act, or an exemption from the registration requirements of the Securities Act is available. No public offering of the securities will be made in the United States. This communication is being distributed only to and is directed only at (a) persons outside the United Kingdom, (b) persons who have professional experience in matters relating to investments, i.e., investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"), and (c) high net worth companies, unincorporated associations and other bodies to whom it may otherwise lawfully be communicated in accordance with Article 49 of the Order (all such persons together being referred to as "relevant persons"). The securities are available only to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be available only to or will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this communication or any of its contents.



About Taj Pharmaceutical Limited

Taj Pharmaceuticals Limited is a pharmaceutical company founded and based in India. The company manufactures pharmaceutical formulations and API for India and other countries of world. The company was established in 1995 as an enterprise and in 2004 became a public limited company. As per Mumbai pharmaxil and Chemixil association the company manufactures and exports to countries like Albania, Argentina, Austria, Chile and Iraq. In 1995 pharmaceuticals wing only has a schedule M certification for pharmaceuticals products manufacturing in India. Taj Pharmaceuticals established its manufacturing unit in Gujarat because of government policies in 1999 with WHO / GMP licence. The company in 2003 revived all the old manufacturing units and approached the FDA Gujarat for 4000 new pharmaceuticals drug permissions for the first time in India.

According to the Indian Trade Mark the company owns about 450 brands and 4600 generic manufacturing permissions in India. According to the export data analysis the company was the largest exporter of generic medicines to the Europe and Middle East countries.

www.tajpharma.com

The company medicines are present in France, Georgia, Egypt and CIF countries.



Taj Pharmaceuticals Limited
Working For Healthier World™ INDIA



Note: This site contains medical information that is intended for doctors or medical practitioner only and is not meant to substitute for the advice provided by a medical professional. Always consult a physician if you have health concerns. Use and access of this site is subject to the terms and conditions as set out in our Privacy Policy and Terms of Use.
© Copyright 2011 Taj Pharma Group (India),. All rights reserved.



Note: This site contains medical information that is intended for doctors or medical practitioner only and is not meant to substitute for the advice provided by a medical professional. Always consult a physician if you have health concerns. Use and access of this site is subject to the terms and conditions as set out in our Privacy Policy and Terms of Use.
© Copyright 2011 Taj Pharma Group (India),. All rights reserved.

Taj Pharmaceuticals Limited (the "Company") believes that the information included in the Investor Relations section of this website was correct at the time it was added to the website. However, the Company expressly disclaims any duty to update the information on the website and makes no representation or warranty as to accuracy and completeness of the contents of this Investors Relations section of the website or any other section of the website. Access to and use of the information on this website is at the user's own risk. The Company assumes no responsibility for any errors or omissions in the content of this website and disclaims any liability for damages of any kind (whether direct, consequential or punitive) arising out of the use of this website or the information contained on the website or on links to or from this website.

The Investor Relations section of this website contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical facts, included on this website regarding the Company's strategy, expected future financial position, results of operations, cash flows, financing plans, discovery and development of products, strategic alliances, competitive position, plans and objectives of management are forward-looking statements. Words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "will" and other similar expressions help identify forward-looking statements, although not all forward-looking statements contain these identifying words. In particular, any statements regarding the Company's financial results and outlook, the continued implementation of the Company's strategic plan, the development of the Company's pipeline, the commencement of Phase 3 clinical trials for Puricase (pegloticase) are forward-looking statements. These forward-looking statements involve substantial risks and uncertainties and are based on current expectations, assumptions, estimates and projections about the Company's business and the biopharmaceutical and specialty pharmaceutical industries in which the Company operates. Such risks and uncertainties include, but are not limited to, the delay or failure in developing Puricase (pegloticase) and other product candidates; difficulties of expanding the Company's product portfolio through in-licensing or acquisition; not being able to manufacture commercial quantities of our products; not gaining market acceptance sufficient to justify development and commercialization costs if our products are approved for marketing; introduction of generic competition for API; fluctuations in buying patterns of wholesalers; potential future returns of API or other products; the Company continuing to incur substantial net losses for the foreseeable future; difficulties in obtaining financing; potential development of alternative technologies or more effective products by competitors; reliance on third-parties to manufacture, market and distribute many of the Company's products; risks of maintaining protection for the Company's intellectual property; risks of an adverse determination in any future intellectual property litigation; and risks associated with stringent government regulation of the biopharmaceutical and specialty pharmaceutical industries and other factors set forth more fully in certain reports filed with the Securities and Exchange Commission, to which investors are referred for further information. The Company may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements, and you should not place undue reliance on the Company's forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that the Company makes. The Company's forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that the Company may make. The Company does not have a policy of updating or revising forward-looking statements and assumes no obligation to update any forward-looking statements.



TAJ

TAJ GROUP
PHARMACEUTICAL
BUSINESS

Further Details Please Visit: www.tajpharma.com

The contents and design of this website, including Authority logos, are the property of the Taj Pharmaceuticals Limited India, and are protected under copyright law and international treaty.

All rights reserved. Except under the conditions described in the Copyright Act 1968 and subsequent amendments, no part of this website may be reproduced or communicated by any process without prior permission in writing from



Copyright © 2004-2011 Taj Pharmaceuticals Limited. All rights reserved. Legal Notice
The products discussed herein may have different product labeling in different countries. The product information provided in this site is intended only for the residents of India.